Biomarkers and MammaPrint Status Predict Breast Cancer Response to Veliparib and Carboplatin

Share this content:
Several mechanism-of-action-based biomarkers predict high-risk HER2-negative breast cancer response to combination therapy.
Several mechanism-of-action-based biomarkers predict high-risk HER2-negative breast cancer response to combination therapy.

Combined with MammaPrint high1/(ultra)high 2 status, several mechanism-of-action-based biomarkers predict high-risk HER2-negative breast cancer response to combination therapy with veliparib and carboplatin (VC), according to findings from the phase 2 I-SPY2 trial (ClinicalTrials.gov Identifier: NCT01042379), presented at the 2016 San Antonio Breast Cancer Symposium.

“By prespecified analyses, PARPi-7, ‘BRCAness,' and MP1/2 specifically predict VC response,” reported Denise Wolf, PhD, of the University of California, San Francisco. “Our sample size is small; we need to validate findings in bigger trials, and in carboplatin as a single treatment.”

I-SPY2 is an adaptively-randomized study platform for testing neoadjuvant treatments. It employs a single controlled arm of patients who receive standard chemotherapy, and up to 4 simultaneous investigational arms. Patients are matched to therapies for which their cancer subtype is proving most responsive, using hormone receptor (HR) and HER2 status and MammaPrint 70-gene signature status. The study's primary endpoint is pathological complete responses (pCR), defined by the absence of residual cancer tissue in breast or lymph tissue.

The trial platform also evaluates biomarkers associated with tested drugs' mechanisms of action. From the candidate biomarkers the authors evaluated, 3 were predictive of pCR in patients treated with VC: PAPRi-7 (a gene-expression signature of DNA damage repair deficiency), BRCAness (a 77-gene BRCA1/2 deficiency signature), and MammaPrint (MP) 1/2 class. There was moderate concordance (50% to 67%) between the VC sensitivity biomarkers, meaning they were not redundant or identifying exactly the same patients, noted Dr Wolf.

RELATED: Veliparib Safe in Combination With Carboplatin and Paclitaxel for BRCA1/2-associated Breast Cancer

Patients who are also MP2 and PARPi7-high were “more sensitive to VC than patients with fewer markers in the ‘sensitive' state, with a prevalence of 40% in triple-negative breast cancer and 9% of HR+/HER2-negative,” Dr Wolf said.

Reference

  1. Wolf DM, Yau C, Sanil A, et al. DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer. Paper presented at: 39th San Antonio Breast Cancer Symposium; Dec 2016; San Antonio, TX.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs